The CD40 Knockout HAP1 Polyclonal Cells consist of a heterogeneous population of human HAP1 cells that have undergone CRISPR/Cas9-mediated disruption of the CD40 gene, generating a diverse array of loss-of-function alleles within the pool. As a polyclonal knockout product, this model circumvents the clonal selection biases of single-cell-derived lines, preserving allelic heterogeneity while enabling robust functional analysis of CD40 signaling. The absence of CD40 protein expression in these cells is a foundation for examining receptor-dependent signaling networks, ligand-receptor interactions, and downstream effector mechanisms.
The HAP1 host cell line is a near-haploid, adherent human cell line originally derived from the KBM-7 chronic myeloid leukemia line. These cells exhibit fibroblast-like morphology and maintain a predominantly haploid karyotype, which simplifies genetic manipulation and reduces functional redundancy. HAP1 cells are extensively validated for use in knockout and mutation screens, providing a consistent background for studying gene function in signal transduction, cancer biology, and immunological processes.
CD40 encodes a costimulatory receptor of the tumor necrosis factor (TNF) receptor superfamily that is primarily expressed on antigen-presenting cells. Canonical activation occurs upon binding of its trimeric ligand CD40L (CD154), leading to the recruitment of TNFR-associated factor (TRAF) adaptors including TRAF2, TRAF3, TRAF5, and TRAF6. These interactions trigger downstream kinases such as TAK1 and IKK, culminating in the activation of NF-??B transcription factors (p65/p50), mitogen-activated protein kinases (ERK, JNK, p38), and the PI3K/AKT signaling cascade. CD40 signaling upregulates key molecules like Bcl-xL, AICDA, CD80, CD86, IL-6, and IL-10, driving B-cell proliferation, antibody class switching, and germinal center formation. Additionally, JAK3 associates with CD40 and contributes to signal propagation.
In the HAP1 haploid background, CD40 knockout enables dissection of receptor-mediated signaling without the confounding influences of wild-type allele expression. This model is particularly valuable for interrogating CD40-dependent NF-??B and MAPK pathway activation, as well as for characterizing the role of CD40 in immune checkpoint biology. Since CD40 dysfunction is implicated in hyper-IgM syndrome type 3, systemic lupus erythematosus, B-cell lymphomas, and other inflammatory diseases, polyclonal knockout cells offer a scalable platform for studying genotype?Cphenotype relationships and therapeutic target validation.
Key research applications include quantitative analysis of downstream signaling events using phospho-specific Western blotting for NF-??B and MAPK, NF-??B luciferase reporter assays, and phospho-kinase arrays. Co-immunoprecipitation of TRAF adaptors can delineate CD40 protein interaction networks. High-throughput drug screening targeting the CD40 pathway is feasible given the homogeneous genetic background of HAP1 cells, and flow cytometry can confirm loss of CD40 surface expression. Furthermore, this model supports investigation of B-cell activation mechanisms and the development of agonists or antagonists for CD40-CD40L blockade. For further inquiries or technical support, please contact Ascent Research.
